NCT06972784 Xiangya Cardiopulmonary Health and Disease Cohort

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30,000 participants in total. It began in 2025-06-01 with a primary completion date of 2035-12-01.

Brief Summary

Xiangya Cardiopulmonary Health and Disease Cohort (XY-CPHDC) is a non-intervention study grounded in real-world data. It is designed as a bidrectional clinical cohort combined retrospective and prospective design, in order to evaluate cardiopulmonary function systematically and holistically, integrate physiology and medical theory, and explore the changing pattern of the cardiopulmonary under different health states. Cardiovascular System and Respiratory System are closely linked and interdependent physiological systems, and they play a vital role in maintaining normal life activities in the human body. Patients with cardiopulmonary disease often have conspicuous comorbidity characteristics, however, current measurements of cardiopulmonary function indicators are mostly limited to the assessments of single organ. This pattern of subspecialty care leads to deficiencies in the recognition of cardiopulmonary synergy dysfunction, and there is an urgent need for a more comprehensive and systematic approach to assessment. This study plans to construct a cardiopulmonary holistic assessment cohort, aiming at comprehensively and systematically reveal the intrinsic connection between the cardiopulmonary function in different scenarios, such as resting, exercise, and sleep, to deeply explore the core indicators of cardiopulmonary holistic function, to construct a joint stratification system of cardiopulmonary function, and to map cardiopulmonary comorbidity spectrum, so that they can accurately guide the diagnosis of the disease, the prognostic prediction and the intervention strategies.

Eligibility Criteria

I1 Inclusion and exclusion criteria for retrospective cohorts 1) Inclusion criteria: 1. Patients were either treated or hospitalized in the physical examination center, outpatient and emergency clinic in the Xiangya Hospital of Central South University from January 2010 to April 2025. 2. Completion of cardiac function (e.g., echocardiography) and pulmonary function (e.g., pulmonary function test) assessment, with an interval of no more than 1 year between the two. 3. Those who had complete clinical diagnostic and therapeutic information (e.g., medical history, medication records, laboratory test results, imaging reports) except for the cardiopulmonary function test report. 2)Exclusion criteria 1. Patients with complete loss of cardiopulmonary function test reports or key data (e.g., VO2peak, FEV1/FVC, LVEF). 2. Patients with loss of key clinical diagnostic and treatment data (e.g., medical history, medication records, laboratory test results). 2.1.2 Inclusion and exclusion criteria for prospective cohort 1）Inclusion criteria 1. Patients who have been included in the retrospective cohort. 2. Voluntarily signed informed consent form to participate in long-term follow-up for ≥3 years. 3. Able to complete the baseline assessment of the prospective cohort (including cardiopulmonary function retesting, questionnaires, etc.). 4. Stable conditions for follow-up (e.g., living in the local area, available valid contact information, no plans to move in the short term or go out for a long period of time). 2\) Exclusion Criteria. 1. Patients who have been excluded from the retrospective cohort or for whom key data are missing. 2. With severe cognitive impairment, psychiatric disease or verbal communication disorder, unable to cooperate with follow-up and data collection. 3. Expected survival time \<3 years (e.g., advanced malignancy, end-stage cardiopulmonary failure, etc.). 4. Incomplete cardiopulmonary function or other clinical data during the baseline assessment. 5. Those who plan to participate in other interventional clinical trials that may interfere with the assessment of cardiopulmonary function.

Contact & Investigator

Frequently Asked Questions

Related Trials